Literature DB >> 10985648

Role of individual drugs in the chemotherapy of tuberculosis.

D A Mitchison1.   

Abstract

During the course of chemotherapy, certain drugs are predominant in their bactericidal activities. Isoniazid is responsible for an initial kill of about 95% of organisms during the first 2 days of treatment. Its bactericidal role is then replaced by rifampicin and pyrazinamide during the intensive phase. In the continuation phase with an isoniazid/rifampicin regimen, rifampicin is the only effective drug against persisters, as shown by the similarity of response by patients with initially isoniazid-resistant or sensitive strains. If the continuation phase regimen does not contain rifampicin but does contain isoniazid, the dominant bactericidal drug is isoniazid. In this case, the response of patients with initial isoniazid resistance is appreciably less good than in those with sensitive organisms. The review suggests exploration in randomised control trials of a continuation phase of rifampicin (or rifapentine) alone. It also suggests the importance of the dose size of rifampicin and the need for exploring a higher dose. Finally, it emphasises the importance of finding drugs that act on persisting organisms that are phenotypically but not genetically resistant to rifampicin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985648

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  98 in total

1.  Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors:  Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

3.  Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis.

Authors:  Rovina Ruslami; Hanneke Nijland; Rob Aarnoutse; Bachti Alisjahbana; Arto Yuwono Soeroto; Suzanne Ewalds; Reinout van Crevel
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

5.  Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  A H Diacon; R F Patientia; A Venter; P D van Helden; P J Smith; H McIlleron; J S Maritz; P R Donald
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 6.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.

Authors:  Daniel Atwine; Maryline Bonnet; Anne-Marie Taburet
Journal:  Br J Clin Pharmacol       Date:  2018-05-22       Impact factor: 4.335

8.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

9.  Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Authors:  Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

10.  Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.

Authors:  Jean-Philippe Lanoix; Thomas Ioerger; Aimee Ormond; Firat Kaya; James Sacchettini; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.